Methylation of NEUROG1 in Serum Is a Sensitive Marker for the Detection of Early Colorectal Cancer

OBJECTIVES:Colorectal cancer is the third most common cancer and a major cause of cancer-related deaths. Early detection of colonic lesions can reduce the incidence and mortality of colorectal cancer. Colonoscopy is the screening test for colorectal cancer with the highest efficacy, but its acceptance in the general public is rather low. To identify suitable tumor-derived markers that could detect colorectal cancer in blood samples, we analyzed the methylation status of a panel of genes in sera of affected patients.METHODS:Using methylation-specific quantitative PCR, we analyzed the methylation of ten marker genes in sera of healthy individuals and patients with colorectal cancer.RESULTS:Only HLTF, HPP1/TPEF, and NEUROG1 DNA methylation was detectable in at least 50% of patients with colorectal cancers. Whereas HLTF and HPP1/TPEF preferentially detected advanced and metastasized colorectal cancers, NEUROG1 methylation was detectable in UICC stages I–IV at a similar rate. Compared with other methylation markers, such as ALX4, SEPT9, and vimentin, NEUROG1 shows a higher sensitivity for colorectal cancer at UICC stages I and II. At a specificity of 91%, NEUROG1 reached a sensitivity of 61% (confidence interval, 50.4–70.6%) for the detection of colorectal cancers. Furthermore, detection of NEUROG1 methylation was independent of age and gender.CONCLUSIONS:Methylation of the NEUROG1 gene is frequently found in sera of patients with colorectal cancers independent of tumor stage. The quantitative detection of NEUROG1 DNA methylation in serum is a suitable approach for the non-invasive screening for asymptomatic colorectal cancer.

[1]  T. Seufferlein,et al.  S3-Leitlinie „Kolorektales Karzinom” – Aktualisierung 2008 , 2008, Zeitschrift fur Gastroenterologie.

[2]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[3]  P. Laird,et al.  Adenocarcinoma Epigenetic Patterns in the Progression of Esophageal Updated Version , 2001 .

[4]  Bela Molnar,et al.  Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. , 2006, Gastroenterology.

[5]  L. Joseph Melton,et al.  A prospective, controlled assessment of factors influencing acceptance of screening colonoscopy , 2002 .

[6]  M. Ziegler,et al.  Attitude to Secondary Prevention and Concerns about Colonoscopy Are Independent Predictors of Acceptance of Screening Colonoscopy , 2010, Digestion.

[7]  A. Zauber,et al.  Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. , 1993 .

[8]  J. Herman,et al.  Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. , 2009, Cancer research.

[9]  G. Friedman,et al.  A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. , 1992, The New England journal of medicine.

[10]  Christian Pilarsky,et al.  Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. , 2009, Clinical chemistry.

[11]  D. Ransohoff,et al.  Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. , 2004, The New England journal of medicine.

[12]  Charles J. Kahi,et al.  Screening, surveillance, and primary prevention for colorectal cancer: a review of the recent literature. , 2008, Gastroenterology.

[13]  P. Maisonneuve,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps. , 2008, Gastroenterology.

[14]  P. Laird,et al.  MethyLight: a high-throughput assay to measure DNA methylation. , 2000, Nucleic acids research.

[15]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[16]  M. Guo,et al.  Epigenetic changes in colorectal cancer , 2013, Chinese journal of cancer.

[17]  J. Herman,et al.  Methylation of TFPI 2 in Stool DNA : A Potential Novel Biomarker for the Detection of Colorectal Cancer , 2009 .

[18]  Valeri Vasioukhin,et al.  Point mutations of the N‐ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia , 1994, British journal of haematology.

[19]  M. Toyota,et al.  Epigenetic changes in solid and hematopoietic tumors. , 2005, Seminars in oncology.

[20]  V A Memoli,et al.  Soluble normal and mutated DNA sequences from single-copy genes in human blood. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  Daiya Takai,et al.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Bela Molnar,et al.  DNA methylation biomarkers for blood-based colorectal cancer screening. , 2008, Clinical chemistry.

[23]  M. Widschwendter,et al.  Methylated DNA as a possible screening marker for neoplastic disease in several body fluids , 2003, Expert review of molecular diagnostics.

[24]  A. Schatzkin,et al.  Colonoscopic screening of average-risk women for colorectal neoplasia. , 2005, The New England journal of medicine.

[25]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[26]  S. Markowitz,et al.  Improved fecal DNA test for colorectal cancer screening. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  J. Herman,et al.  Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. , 2001, Human molecular genetics.

[28]  R. Lamerz,et al.  Analysis of promoter methylation in stool: a novel method for the detection of colorectal cancer. , 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[30]  D. Sargent,et al.  Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia , 2008, Annals of Internal Medicine.

[31]  L. Melton,et al.  A prospective, controlled assessment of factors influencing acceptance of screening colonoscopy , 2002, American Journal of Gastroenterology.

[32]  Hermann Brenner,et al.  Blood Markers for Early Detection of Colorectal Cancer: A Systematic Review , 2007, Cancer Epidemiology Biomarkers & Prevention.

[33]  Douglas K Rex,et al.  Corrigendum: American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2009, The American Journal of Gastroenterology.

[34]  T. Morikawa,et al.  A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. , 2005, Gastroenterology.

[35]  R. Lamerz,et al.  Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence , 2009, European journal of gastroenterology & hepatology.

[36]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[37]  Perry J Pickhardt,et al.  Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi‐Society Task Force on Colorectal Cancer, and the American College of Radiology * † , 2008, CA: a cancer journal for clinicians.

[38]  B. Levin,et al.  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. , 2008, Gastroenterology.

[39]  S. Goodman,et al.  Sensitive digital quantification of DNA methylation in clinical samples , 2009, Nature Biotechnology.

[40]  R. Ward,et al.  Colorectal cancer: a model for epigenetic tumorigenesis , 2006, Gut.

[41]  R. Lamerz,et al.  Methylation of Serum DNA Is an Independent Prognostic Marker in Colorectal Cancer , 2006, Clinical Cancer Research.

[42]  U. Lindforss,et al.  Allelic loss is heterogeneous throughout the tumor in colorectal carcinoma , 2000, Cancer.